Our Science
Antibody Drug Conjugates (ADCs):
Daiichi Sankyo’s DXd ADC Technology
At the forefront of Daiichi Sankyo’s oncology pipeline is our DXd ADC Technology.
Changing Medicine Now
We continuously develop and expand our robust pipeline to address patients’ unmet medical needs. Our pursuit of new medicines is fueled by the scientific curiosity of our employees, a willingness to examine new ideas, and the pairing of existing information with novel concepts.
Developing Medicines
Clinical trials help make progress against diseases possible by testing the safety and efficacy of potential new medicines.
Our R&D strategy seeks to expand & extend our portfolio to deliver our technology to more patients.
Each medicine must be evaluated for efficacy and safety before becoming available by prescription.
Our R&D strategy seeks to expand & extend our portfolio to deliver our technology to more patients.
Each medicine must be evaluated for efficacy and safety before becoming available by prescription.
Daiichi Sankyo Externally
Sponsored Research
Sponsored Research
Daiichi Sankyo is committed to the advancement of research that will help improve patient lives around the world. If you are interested in conducting your own research related to Daiichi Sankyo’s areas of therapeutic expertise, we may provide funding or other forms of support.
WORLDWIDE
OPERATIONS
OPERATIONS
Remaining Inclusive at Our Core, Global in Our Impact
We’re dedicated to the enrichment of quality of life around the world.
Expanded Access to Investigational Products
Early access to investigational medicine may be granted for critically ill patients.